Since the 1970s, clinicians have increasingly become more familiar with hyperprolactinemia
(HPRL) as a common adverse effect of antipsychotic medication, which remains the …

Dopamine partial agonism and functional selectivity have been innovative strategies in the
pharmacological treatment of schizophrenia and mood disorders and have shifted the …

Antipsychotics represent the mainstay of schizophrenia pharmacological therapy, and their
role has been expanded in the last years to mood disorders treatment. Although introduced …

Emerging researches point to a relevant role of postsynaptic density (PSD) proteins, such as
PSD-95, Homer, Shank, and DISC-1, in the pathophysiology of schizophrenia and autism …

Dopamine-glutamate interplay dysfunctions have been suggested as pathophysiological
key determinants of major psychotic disorders, above all schizophrenia and mood disorders …

Emerging evidence from genomics, post-mortem, and preclinical studies point to a potential
dysregulation of molecular signaling at postsynaptic density (PSD) in schizophrenia …

Schizophrenia is a severe psychiatric illness affecting almost 25 million people worldwide
and is conceptualized as a disorder of synaptic plasticity and brain connectivity …

Schizophrenia is a severe mental illness characterized by alterations in processes that
regulate both synaptic plasticity and functional connectivity between brain regions …

An increasing amount of research aims at recognizing the molecular mechanisms involved
in long-lasting brain architectural changes induced by antipsychotic treatments. Although …

Administration of NMDA receptor antagonists, such as ketamine and MK-801, may induce
psychotic-like behaviors in preclinical models of schizophrenia. Ketamine has also been …